AbCellera
AbCellera Biologics Inc., headquartered in Vancouver, Canada, is a pioneering biotechnology company that focuses on the discovery and development of monoclonal antibodies. Founded in 2012, AbCellera has rapidly established itself as a leader in the biopharmaceutical industry, leveraging its innovative antibody discovery platform to accelerate the development of therapeutics. The company’s unique technology integrates advanced machine learning and high-throughput screening, enabling the rapid identification of antibodies from natural immune responses. Notable achievements include collaborations with major pharmaceutical companies and a significant role in the development of COVID-19 treatments. With a strong market position, AbCellera continues to drive advancements in antibody therapeutics, making substantial contributions to the field of immunology and drug development.
DitchCarbon Score
How does AbCellera's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AbCellera's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AbCellera's reported carbon emissions
AbCellera, headquartered in Canada, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. The company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As of now, AbCellera's climate strategy appears to be in the early stages, with no significant initiatives or targets publicly outlined. The absence of emissions data and reduction commitments suggests that the company may still be developing its approach to sustainability and climate impact. In the context of the biotechnology industry, it is increasingly important for companies to adopt transparent climate strategies and set measurable targets to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AbCellera is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
